CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma

STATUS

Recruiting
End date

Dec 10, 2023
participants needed

30
sponsor

City of Hope Medical Center

Send

Updated on 4 February 2022

See if I qualify

platelet count

fludarabine

cyclophosphamide

ejection fraction

serum pregnancy test

measurable disease

growth factor

cell transplantation

gilbert's syndrome

neutrophil count

autograft

line of therapy

proteasome inhibitor

plasmacytoma

bone marrow plasma cells

Summary

This phase I trial studies the side effects and best dose of CS1-chimeric antigen receptor (CAR) T therapy after chemotherapy in treating patients who have CS1 positive multiple myeloma that has come back (relapsed) or does not respond to treatment (refractory). Immune cells can be engineered to kill multiple myeloma cells by inserting a piece of deoxyribonucleic acid (DNA) into the immune cells using a lentiviral vector such as CS1, that allows them to recognize multiple myeloma cells. These engineered immune cells, CS1-CAR T cells, may kill multiple myeloma cells.

Description

PRIMARY OBJECTIVE:

I. To evaluate the safety and tolerability of intravenous (i.v.) delivered autologous CS1-CAR T cells for research participants with CS1+ recurrent/refractory multiple myeloma (MM).

SECONDARY OBJECTIVES:

I. Evaluate the response rates at days 28, 100, and 180 post CAR T cell infusion.

II. Measure the persistence of CS1-CAR T cells in blood and marrow. III. Measure phenotype and anti-tumor functionality of CS1-CAR T cells in marrow and blood.

IV. Measure the levels of cytokines in blood and marrow, and soluble CS-1 in blood post infusion as a surrogate indicator of CAR T cell activity.

V. Evaluate CS-1 expression on MM cancer cells before, during and at progressive disease (PD) to determine antigenic loss.

EXPLORATORY OBJECTIVE:

I. Describe the percentage of MM cells that express CS-1 surface marker before, during and at PD.

OUTLINE: This is a dose-escalation study of CS1-CAR T cells.

Patients undergo leukapheresis over 2-4 hours. Beginning 3-4 weeks, patients receive cyclophosphamide intravenously (IV) on days -4 and/or -3 or fludarabine IV and cyclophosphamide IV on days -5 to -3. Patients then undergo CS1-CAR T therapy over 10-15 minutes on day 0.

After completion of study treatment, patients are followed up at 1 day, at least every 2 days for up to a minimum of 14 days, weekly for 1 month, monthly for 1 year, then periodically for up to 15 years.

Details

Condition	Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Treatment	cyclophosphamide, leukapheresis, Fludarabine, CS1-CAR T Therapy
Clinical Study Identifier	NCT03710421
Sponsor	City of Hope Medical Center
Last Modified on	4 February 2022

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	Documented informed consent of the participant and/or legally authorized representative
	Assent, when appropriate, will be obtained per institutional guidelines
	Karnofsky Performance Status (KPS) of >= 70%
	Life expectancy >= 16 weeks
	Participant must have a confirmed diagnosis of active MM as defined by the International Myeloma Working Group (IMWG) criteria
	Participant must have a confirmed CS1+ MM as evaluated by City of Hope (COH) Pathology Core
	Participant must have measurable disease defined as meeting at least one of the criteria below
	Serum M-protein >= 0.5 g/dL
	Urine M-protein >= 200 mg/24 hour
	Involved serum free light chain (sFLC) level >= 10 mg/dL with abnormal kappa/lambda ratio
	Measurable biopsy-proven plasmacytomas (>= 1 lesion that has a single diameter >= 2 cm)
	Bone marrow plasma cells >= 30%
	Participant must have relapsed or refractory disease after all 3 prior treatment regimens with the following requirements
	Participant must have received prior treatment with an immunomodulatory agent
	Participant must have received prior treatment with a proteasome inhibitor
	Participant must have received prior treatment with an anti-CD38 antibody
	Participants must be refractory to last line of therapy prior to study enrollment (refractory myeloma is defined as disease that is nonresponsive, progression on treatment, or shows progression within 60 days after the last prior line of therapy)
	Participants who were not candidates to receive one or more of the above treatments are eligible; however, the reason must be clearly documented in the case report form
	Note: induction chemotherapy, autologous stem-cell transplantation (ASCT), and maintenance therapy should be considered as 1 "regimen
	Additionally, if a participation underwent autologous transplant he/she be >= 90 days from transplant at the time of enrollment
	Total serum bilirubin =< 2.0 mg/dL
	Participants with Gilbert syndrome may be included if their total bilirubin is =< 3.0
	Aspartate aminotransferase (AST) < 2.5 x upper limit of normal (ULN)
	Alanine aminotransferase (ALT) < 2.5 x ULN
	Serum creatinine =< 2.5 x ULN or estimated creatinine clearance of >= 40 mL/min per the Cockcroft-Gault formula, and the participant is not on hemodialysis
	Absolute neutrophil count >= 1000/uL. Transfusions and growth factors must not be used to meet these requirements at initial screening
	Hemoglobin (Hb) >= 8 g/dl. Transfusions and growth factors must not be used to meet these requirements at initial screening
	Platelet count >= 50,000/uL (>= 30,000/uL if bone marrow plasma cells are >= 50% of cellularity). Transfusions and growth factors must not be used to meet these requirements at initial screening
	Left ventricular ejection fraction >= 45% within 8 weeks before enrollment
	Oxygen (O2) saturation >= 92%
	Women of childbearing potential (WOCBP): Negative urine or serum pregnancy test
	If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
	Agreement by females and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 3 months after the last dose of protocol therapy
	Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only)
Exclusion Criteria
	Prior allogeneic stem cell transplantation
	Autologous transplantation =< 90 days of enrollment
	Growth factors within 14 days of enrollment
	Platelet transfusions within 7 days of enrollment
	Epstein-Barr virus (EBV) positivity by polymerase chain reaction (PCR) at the time of enrollment
	Participants receiving any other investigational agents, or concurrent biological, chemotherapy, or radiation therapy
	Participants with known additional malignancy that is progressing or required active treatment within the last 2 years. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy
	Participants with toxicities from prior therapies, with the exception of peripheral neuropathy attributable to bortezomib, that have not recovered to grade =< 2 according to the Common Terminology Criteria for Adverse Events (CTCAE) 5.0 criteria or to the subject's prior baseline
	Participants with known active hepatitis B or C infection; research participants who are human immunodeficiency virus (HIV) positive based on testing performed within 4 weeks of enrollment; research participants with any signs or symptoms of active infection, positive blood cultures or radiological evidence of infections
	Participants with active auto-immune disease, including connective tissue disease, sarcoidosis, multiple sclerosis, inflammatory bowel disease or have a history of severe (as judged by the principal investigator) autoimmune disease that will require prolonged immunosuppressive therapy
	Have New York Heart Association (NYHA) Class III or IV heart failure, unstable angina, or a history of recent (within 6 months) myocardial infarction
	Participants with a history or presence of clinically relevant central nervous system (CNS) pathology such as uncontrolled seizure disorder, stroke, severe brain injuries, dementia, cerebellar disease or psychosis
	Participants with known active central nervous system (CNS) involvement by malignancy. Subjects with prior CNS disease that has been effectively treated will be eligible if treatment was completed at least 3 months prior to enrollment with no evidence of symptomatic disease and stable abnormalities on repeat imaging
	Participants with plasma cell leukemia (PCL) or symptomatic amyloidosis. However, participants with a prior history of PCL are not excluded
	Participants with any known contraindications to leukapheresis, cyclophosphamide, fludarabine, cetuximab or tocilizumab
	Dependence on corticosteroids
	Defined as doses of corticosteroids of greater than or equal to 10 mg/day of prednisone or equivalent doses of other corticosteroids
	Note: Topical and inhaled corticosteroids in standard doses and physiologic replacement for subjects with adrenal insufficiency are allowed
	Participants with inadequate venous access for leukapheresis, and who are either unable to or unwilling to have a supportive line (temporary or other) placed for the procedure
	Females only: Pregnant or breastfeeding
	Any other condition that would, in the Investigator's judgment, contraindicate the subject's participation in the clinical study due to safety concerns with clinical study procedures
	Prospective subjects who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

bone marrow plasma cells

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Edit Delete

Added by •

•

Private

Edit Delete

Reply by • • Private

Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

Enter the passcode

The passcode will expire in None.

CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma